Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pharmather Hldgs Ltd
(OP:
PHRRF
)
0.1550
-0.0051 (-3.19%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
209,140
Open
0.1675
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.1601
Today's Range
0.1500 - 0.1675
52wk Range
0.0831 - 0.3200
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
August 21, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
August 19, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Performance
YTD
-37.25%
-37.25%
1 Month
-8.72%
-8.72%
3 Month
+9.31%
+9.31%
6 Month
-1.59%
-1.59%
1 Year
+50.34%
+50.34%
More News
Read More
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
May 15, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
May 10, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
May 01, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 18, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 16, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
April 02, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
February 21, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
February 12, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Via
Benzinga
PharmaTher Provides Update for Expected FDA Approval of Ketamine
January 10, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
October 02, 2023
Via
Benzinga
PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
September 27, 2023
Via
Benzinga
Exposures
Product Safety
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
September 27, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
September 12, 2023
Via
Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
September 11, 2023
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
September 06, 2023
Via
Benzinga
Exposures
Product Safety
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
September 06, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
July 24, 2023
Via
Benzinga
PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
July 18, 2023
Via
Benzinga
PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
July 18, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
Via
Benzinga
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
June 28, 2023
Via
Benzinga
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
June 27, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.